Healthcare / BiotechnologyKOSDAQ
$916.00
-82.00 (-8.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-9.7B · quality 57.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$55.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-30.5%
↓Gross Margin
48.2%
↓Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+113.9%
FCF CAGR
—
FCF margin
-276.5%
FCF / Net income
1.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.50B · net income $-8.62B · FCF $-9.69B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.50B | $3.50B | $1.08B | $243.2M | $358.3M |
| Net Income | $-8.62B | $-8.62B | $-8.70B | $-13.60B | $-7.12B |
| EBITDA | $-7.19B | $-7.19B | $-6.47B | $-11.65B | $-7.50B |
| EPS | -276.00 | -276.00 | -494.00 | -654.65 | -171.22 |
| Gross Margin | 48.2% | 48.2% | 71.3% | 78.6% | 80.0% |
| Operating Margin | -222.6% | -222.6% | -651.2% | -5019.5% | -2322.3% |
| Net Margin | -246.0% | -246.0% | -803.7% | -5593.0% | -1986.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.08 | 0.54 | 0.24 |
| Cash Flow | |||||
| Free Cash Flow | $-9.69B | $-9.69B | $-7.04B | $-11.54B | $-6.08B |
| Returns | |||||
| ROE | -30.5% | -30.5% | -34.2% | -87.9% | -24.3% |
| Valuation | |||||
| P/B | 1.02 | 1.02 | 0.80 | 4.95 | 6.07 |
| Growth & Yield | |||||
| Revenue Growth | 223.7% | 223.7% | 345.3% | -32.1% | — |
| EPS Growth | 44.1% | 44.1% | 24.5% | -282.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-34.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-494.00 → -276.00
Residual
-34.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.